Evidence based medicine (EBM) is here to stay. Purchasers of health care will demand evidence for clinical interventions and services and will want the best quality evidence of effectiveness to justify resources. An important recent development has been the agreement by the GRADE working group, a large collaboration of influential guideline developers and EBM institutions, on a system of grading recommendations.'
The development of a widely accepted system of grading of evidence has been a long time coming. In the previous hierarchy equal weight might have been given to a poor-quality, small-scale randomised controlled trial (RCT) and a well-designed, multi-centre RCT. This was not a sustainable position and a number of attempts were made to refine this system. For over a decade, the system of grading evidence for clinical guidelines has been progressively refined to take account of the quality of the design and reporting of research.2 '3 The beauty of the new system is the simplicity with which it grades evidence and gives recommendations. Previously, the same piece of evidence might be graded. 11-2, B; C+, 1; or strong evidence, strongly recommended. This is confusing for users of guidelines when the question they are asking of a clinical guideline isshould I do this or not? The new system will simply grade the evidence high, low or very low and make recommendations as "'do it", don't do it" " probably do it" or "probably don't do it".
Whilst this is easier for users, it will require a great deal of work by guideline producers in sifting and grading evidence. They will have to grade evidence, firstly, on study methodology (randomised trial =high, observational study= low, any other evidence=very low) with decreases in grade due to limitations in the study methodology (important inconsistencies, imprecise or sparse data or high probability of reporting bias). However, there will be the ability to upgrade evidence if there is a strong or very strong evidence of association or consistent evidence from two or more observational studies, with no plausible confounders.
What is still uncertain is the place of qualitative research in the system of grading evidence. Given that the current systems of evidence grading are based on the rigid application of scientific method to critical appraisal, it may be that a different, parallel system may need to be t Arnold 2004 developed by those skilled in appraising this literature. The EBM paradigm just may not work for qualitative evidence.
The effect of the new grading system, properly applied, should be to allow more transparency to the process of citing evidence in clinical guidelines. It also allows a more subtle and nuanced weighting of clinical judgement which remains the key to interpreting the evidence on a particular clinical question. Working backwards in the evidence process, it should allow researchers to ask themselves in the design and reporting of their research how can this work change practice? If the right attention is paid to the design and reporting of studies, evidence of the best quality will change practice.
There is an epistemological question at stake in assessing research evidencehow do we know what we think we know? Taking an extreme example on the use of opiates in dyspnoea 4 one study is cited as an RCT of 4 patients.5 Such a spectacularly underpowered study would only offer useful evidence if the effect size of the intervention was vast. It wasn't and such evidence adds nothing to our ability to make a clinical judgement.
Whilst it is acknowledged that the evidence base is small in areas of palliative medicine6-8 it does not help by falling prey to what the late Professor Petr Skrabanek called the "Faggot Fallacy".9 For readers in North America it should be explained that a faggot in Britain is a bundle of sticks tied togetherhence the faggot fallacy is the bundling together of weak pieces of evidence in an attempt to make something more substantial. Collections of related weak evidence just make lots of weak evidencethey are no stronger for being grouped together.
The key issue for researchers in palliative care is not that they should necessarily aim to produce evidence from the higher points in the hierarchy (i.e. systematic reviews and RCTs) but that the design and reporting of their research should be such that it reaches the highest quality ratings. The absolute level of evidence is not always that germanenot every clinical question can be answered by an RCT.
Research in palliative care must have at its heart a belief that the production of good quality evidence is a matter of justice and that dying patients and their loved ones deserve to know that the services and interventions provided by palliative care services are effective in the same way that this is rightly demanded by other patients.
